We are Merus

Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics®, which are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical studies to have similar features as conventional monoclonal antibodies, such as long half-life and low immunogenicity.

Management Team

Ton Logtenberg, Ph.D.

President, Chief Executive Officer & Principal Financial Officer

Mark Throsby, Ph.D.

EVP & Chief Scientific Officer

L. Andres Sirulnik, M.D. Ph.D.

EVP & Chief Medical Officer

Lex Bakker, Ph.D.

SVP & Chief Development Officer

John de Kruif, Ph.D.

SVP & Chief Technology Officer

Hui Liu, Ph.D.

EVP, Chief Business Officer & Head of Merus U.S.

Peter B. Silverman, J.D.

EVP & General Counsel
Ton Logtenberg, Ph.D.
President, Chief Executive Officer & Principal Financial Officer

Ton Logtenberg, Ph.D. has served as our President & Chief Executive Officer and an executive board member since co-founding our company in June 2003, and has served as our Principal Financial Officer since January 2019. Dr. Logtenberg also serves as President of our subsidiary, Merus US, Inc.

Prior to joining Merus, Dr. Logtenberg co-founded Crucell N.V., a biotechnology company specializing in vaccines and biopharmaceutical technology, and served as its executive vice president and chief scientific officer from July 2000 until November 2003.

Dr. Logtenberg has served as a member of the board of directors of the Jenner Foundation since 2008, a member of the board of directors of Utrecht Science Park since November 2014, and a member of the supervisory board of the HUB Foundation since August 2018. Dr. Logtenberg holds a Ph.D. in medical biology from Utrecht University.

Mark Throsby, Ph.D.
EVP & Chief Scientific Officer

Mark Throsby, Ph.D. has served as our Chief Scientific Officer since January 2013 and previously served as our Chief Operating Officer from October 2008 to January 2013. His responsibilities include strategic scientific leadership, management of discovery, pre-clinical research and translational research, business development support, external collaborations and partnerships management.

Before joining Merus, from October 2000 to October 2008, he served as a senior scientist and then as director of antibody discovery for Crucell N.V., a biotechnology company specializing in vaccines and biopharmaceutical technology. Dr. Throsby holds a Ph.D. in immunology from Monash University.

L. Andres Sirulnik, M.D. Ph.D.
EVP & Chief Medical Officer

Andres Sirulnik, M.D., Ph.D. has served as our Chief Medical Officer since October 2016. His responsibilities include clinical strategy and development.

Prior to joining Merus, Dr. Sirulnik was at Novartis Pharmaceuticals from 2008 to 2016, most recently serving as Vice President – Senior Global Clinical Program Head and Research Physician in Oncology Clinical Development. From 2003 to 2008, Dr. Sirulnik was an attending physician in the leukemia program at Dana Farber Cancer Institute and Instructor in Medicine at Harvard Medical School where he focused his research and clinical work in rare hematologic malignancies.

Dr. Sirulnik received his medical degree from the University of Buenos Aires, Argentina, and his Ph.D. in medicine and molecular biology at the University of Cambridge, England.

Lex Bakker, Ph.D.
SVP & Chief Development Officer

Lex Bakker, Ph.D. has served as our Chief Development Officer since October 2010. His responsibilities include strategic scientific leadership, management of preclinical and clinical development and manufacturing, business development support, external collaboration and partnership management.

Prior to joining Merus, Dr. Bakker directed preclinical and clinical development at Crucell N.V., a biotechnology company. Mr. Bakker holds a Ph.D in Tumor Immunology from the University of Nijmegen and was a postdoctoral fellow at the DNAX Research Institute.

John de Kruif, Ph.D.
SVP & Chief Technology Officer

John de Kruif, Ph.D. has served as our Chief Technology Officer since January 2013 and previously served as our Chief Scientific Officer from April 2007 to January 2013. His responsibilities include management of antibody discovery, antibody engineering, external collaborations, partnerships management and operational activities.

Before joining Merus, from October 2000 to October 2006, he served as a director of antibody discovery for Crucell N.V., a biotechnology company specializing in vaccines and biopharmaceutical technology. Dr. de Kruif holds a PhD in Antibody Engineering from Utrecht University.

Hui Liu, Ph.D.
EVP, Chief Business Officer & Head of Merus U.S.

Hui Liu, Ph.D. has served as our Chief Business Officer since December 2015 and Head of Merus U.S. since October 2018. His responsibilities include all aspects of business development, including in- and out- licensing, acquisitions and alliance management, and expansion of Merus in the U.S. Prior to joining Merus, Dr. Liu served as Vice President and Global Head, Business Development & Licensing, Oncology at Novartis AG, a pharmaceutical company, from 2013 to 2015, and as Vice President and Global Head, Business Development & Licensing, Vaccines & Diagnostics, from 2009 to 2012.

Prior to Novartis, Dr. Liu held various management positions at Pfizer, Inc., a pharmaceutical company, from 2004 to 2009 and at Pfizer, Inc. and its predecessor company Warner-Lambert from 1997 to 2001. From 2001 to 2004, Dr. Liu was an investment banker at Goldman Sachs and Citigroup. Dr. Liu holds a Ph.D. in molecular biology and an M.B.A. in finance from the University of Michigan and a B.S. in biology from Peking University.

Peter B. Silverman, J.D.
EVP & General Counsel

Peter B. Silverman, J.D. has served as our General Counsel since February 2018 and our Chief Intellectual Property Officer and Head of US Legal since February 2017. His responsibilities include all aspects of the company’s legal and intellectual property matters.

Prior to joining Merus, Mr. Silverman was a Partner at Kirkland & Ellis LLP, where he represented numerous life sciences companies concerning an array of legal matters. Mr. Silverman also served as judicial law clerk to U.S. District Court Judge Anne E. Thompson of the District of New Jersey. He holds a J.D. from Fordham University School of Law, graduating magna cum laude and Order of the Coif. He is admitted to practice law in New York. Mr. Silverman also holds a B.A. in biology from the University of Rochester.

Board of Directors

Russell G. Greig

Chairman

Ton Logtenberg, Ph.D.

President, Chief Executive Officer & Principal Financial Officer

Mark Iwicki

Non-Executive Director

Len Kanavy

Non-Executive Director

John de Koning, Ph.D.

Non-Executive Director

Gregory D. Perry

Non-Executive Director

Anand Mehra, M.D.

Non-Executive Director

Victor Sandor, M.D.

Non-Executive Director

Bill Lundberg, M.D.

Non-Executive Director

Anne Noordzij

Secretary
Russell G. Greig
Chairman

Russell G. Greig, Ph.D. has served as the Chairman of our board of directors and been a non-executive member of the board since July 2018. Dr. Greig worked at GlaxoSmithKline for three decades, most recently as President of SR One, GlaxoSmithKline’s corporate venture group.

Prior to joining SR One, he served as President of GlaxoSmithKline’s Pharmaceuticals International from 2003 to 2008, as well as on the GlaxoSmithKline corporate executive team. Currently, Dr. Greig serves as the Chairman of: AM Pharma and MedEye Solutions  in the Netherlands, eTheRNA in Belgium, and Sanifit in Spain.

He was previously Chairman of Ablynx in Belgium (acquired by Sanofi, France), Isconova in Sweden (acquired by Novavax, United States), Novagali in France (acquired by Santen, Japan), Syntaxin in the United Kingdom (acquired by Ipsen, France) and Bionor in Norway, as well as board member of TiGenix in Belgium (acquired by Takeda, Japan), Oryzon in Spain and Onxeo Pharma (previously BioAlliance Pharma) in France, and a venture partner at Kurma Life Sciences (Paris, France).

Ton Logtenberg, Ph.D.
President, Chief Executive Officer & Principal Financial Officer

Ton Logtenberg, Ph.D. has served as our President & Chief Executive Officer and an executive board member since co-founding our company in June 2003, and has served as our Principal Financial Officer since January 2019. Dr. Logtenberg also serves as President of our subsidiary, Merus US, Inc.

Prior to joining Merus, Dr. Logtenberg co-founded Crucell N.V., a biotechnology company specializing in vaccines and biopharmaceutical technology, and served as its executive vice president and chief scientific officer from July 2000 until November 2003.

Dr. Logtenberg has served as a member of the board of directors of the Jenner Foundation since 2008, a member of the board of directors of Utrecht Science Park since November 2014, and a member of the supervisory board of the HUB Foundation since August 2018. Dr. Logtenberg holds a Ph.D. in medical biology from Utrecht University.

Mark Iwicki
Non-Executive Director

Mark Iwicki has been a non-executive member of our board of directors since June 2015. From June 2015 until July 2018, Mr. Iwicki served as the Chairman of our board of directors. Mr. Iwicki is the chief executive officer and chairman of the board of directors of Kala Pharmaceuticals, Inc. and serves as a member of the boards of directors of Aimmune Therapeutics, Inc., Nimbus Therapeutics, Oxeia Biopharmaceuticals and Akero Therapeutics, Inc. In addition, Mr. Iwicki has served on the board of the Wellesley Youth Hockey Association.

Mr. Iwicki served as president and chief executive officer and a member of the board of directors of Civitas Therapeutics, Inc. from January 2014 until its acquisition by Acorda Therapeutics, Inc. in October 2014. From December 2012 to January 2014, Mr. Iwicki served as president and chief executive officer and director at Blend Therapeutics, Inc. From 2007 to June 2012, Mr. Iwicki was president and chief executive officer and director of Sunovion Pharmaceuticals, Inc., formerly Sepracor, Inc. Mr. Iwicki holds an M.B.A. from Loyola University.

Len Kanavy
Non-Executive Director

Len Kanavy has been a non-executive member of our board of directors since July 2018. Mr. Kanavy most recently served as Senior Vice President, Commercial Business Operations at Genentech where he was responsible for strategic decisions of the U.S. commercial business including product launches, valuation of business development opportunities, clinical development plan options and pricing. He was a Board Member of the Genentech Access to Care Foundation.

Prior to joining Genentech, Mr. Kanavy was Vice President, Commercial Operations at Novartis Pharmaceuticals, where he led teams in business analytics, strategy, and product launches. He currently serves on the board of privately held KMK Consulting. Mr. Kanavy holds a B.S. in Business Administration and an MBA with a specialization in Finance from the University of Scranton.

John de Koning, Ph.D.
Non-Executive Director

John de Koning, Ph.D. was nominated to serve on our board of directors by Coöperatief LSP IV U.A., one of our shareholders, and has been a non-executive member of our board of directors since January 2010. Dr. De Koning has been a partner at LSP (Life Sciences Partners) since January 2006. Dr. De Koning currently serves on the boards of the private companies GTX medical, eTheRNA and Aelin Therapeutics.

Previously, he served on the supervisory boards of BMEYE (acquired by Edwards Lifesciences), Prosensa (acquired by BioMarin) and Skyline Diagnostics, and as a non-executive director on the boards of argenx, Pronota (acquired by MyCartis) and Innovative Biosensors Inc. Dr. De Koning holds an M.Sc. in medical biology from Utrecht University and a Ph.D. in oncology from the Erasmus University Rotterdam.

Gregory D. Perry
Non-Executive Director

Gregory D. Perry has been a non-executive member of our board of directors since May 2016 and Vice Chairman of our board of directors since August 2018. Mr. Perry is the Chief Financial Officer at Finch Therapeutics Group and serves as a member of the Board of Directors of Kala Pharmaceuticals. Mr. Perry served as Chief Financial and Administrative Officer of Novelion Therapeutics Inc. or Novelion, a public company, from November 2016 to December 2017.

Prior to this, Mr. Perry was Chief Financial Officer of Aegerion Pharmaceuticals Inc., a public company, from July 2015 until its merger with Novelion in November 2016. Prior to that, he served as Chief Financial and Business Officer of Eleven Biotherapeutics, Inc., a public company, from January 2014 to June 2015. Before joining Eleven Biotherapeutics, Mr. Perry served as the Interim Chief Financial Officer of InVivo Therapeutics, a public company, from September 2013 to December 2013, and prior to that he served as the Senior Vice President and Chief Financial Officer of ImmunoGen, Inc., a public company, from 2009 until he was promoted in 2011 to Executive Vice President and Chief Financial Officer, a role he held until 2013. Before that, he was the Chief Financial Officer of Elixir Pharmaceuticals. Mr. Perry previously was Senior Vice President and Chief Financial Officer of Transkaryotic Therapies. He has also held various financial leadership roles within PerkinElmer Inc., Domantis Ltd., Honeywell and General Electric. Since February 2018, Mr. Perry has served on the Board of Directors of Kala Pharmaceuticals, including as Chair of its Audit Committee. From December 2011 to February 2016, Mr. Perry served on the Board of Directors of Ocata Therapeutics (a public biotechnology company), including as Chair of its Audit Committee and a member of its Compensation Committee, until it was acquired by Astellas Pharma Inc. Mr. Perry received a B.A. in Economics and Political Science from Amherst College.

Anand Mehra, M.D.
Non-Executive Director

Anand Mehra, M.D. was nominated to serve on our board of directors by Sofinnova Venture Partners IX, L.P., one of our shareholders, and has been a non-executive member of our board of directors since August 2015. Dr. Mehra has been with Sofinnova Investments (f.k.a. Sofinnova Ventures) since 2007, most recently holding the position of a general partner where he focuses on working with entrepreneurs to build drug development companies. He has led the firm’s investments in Vicept Therapeutics (acquired by Allergan), Aerie Pharmaceuticals, Inc., Aclaris Therapeutics, Inc., and Prothena Corporation PLC.

He currently serves as a member of the boards of directors of Spark Therapeutics, Inc. and Aclaris Therapeutics, Inc., as well as on the boards of several private companies. Dr. Mehra holds his M.D. from Columbia University’s College of Physicians and Surgeons.

Victor Sandor, M.D.
Non-Executive Director

Victor Sandor, M.D. has been a non-executive director member of our board of directors since June 2019.  Dr. Sandor has more than 15 years of experience in the pharmaceutical and biotechnology industries. He is currently Chief Medical Officer at Array BioPharma where he was instrumental in obtaining the approval of Braftovi and Mektovi for the treatment of BRAFV600E/K mutant melanoma. Prior to joining Array, he was Senior Vice President for Global Clinical Development at Incyte Corporation where he played a critical role in the approval of Jakafi for the treatment of  Myelofibrosis and Polycythemia Vera. Dr. Sandor was also Vice President and Chief Medical Officer for oncology at Biogen Idec and  held positions of increasing responsibility in oncology product development at AstraZeneca, where he played an important role in the registration of Arimidex(r) (anastrozole) for adjuvant use and the development of several early stage programs through proof of concept. Dr. Sandor received his MD CM from McGill University in Montreal, Canada, and completed his Fellowship in Medical Oncology at the National Institutes of Health in Bethesda, Maryland.

Bill Lundberg, M.D.
Non-Executive Director

Bill Lundberg, M.D. has been a non-executive director of our board of directors since June 2019. Dr. Lundberg has more than 15 years of experience in the pharmaceutical and biotechnology industries. Prior to joining the board, he was Chief Scientific Officer and the first US employee of CRISPR Therapeutics. He was responsible for establishing and growing R&D in the US and overseeing the first company CRISPR-based product from inception to regulatory filing for clinical trials.  He was also Vice President and Head of Translational Medicine at Alexion, overseeing R&D from discovery through early development, as well as Director and Chief Medical Officer of Taligen Therapeutics. He has previously held roles of increasing responsibility in clinical drug development and medical affairs at Xanthus/Antisoma, Wyeth (now Pfizer), and Genzyme. Dr. Lundberg received an MD from Stanford and an MBA from the University of Massachusetts. He completed post-doctoral training at the Whitehead Institute/MIT, and clinical training in Medicine and Medical Oncology from Harvard and the Dana-Farber Cancer Institute.

Anne Noordzij
Secretary

Scientific Advisory Board

Johannes Carolus Clevers, M.D., Ph.D.

Antoni Ribas, M.D., Ph.D.

Ton Schumacher, Ph.D.

Josep Tabernero, M.D., Ph.D.

Johannes Carolus Clevers, M.D., Ph.D.

Dr. Clevers is a Professor of Molecular Genetics at the University Medical Center Utrecht and Director of Research at the Princess Máxima Center for Pediatric Oncology. For ten years, Dr. Clevers served as the Director of the Hubrecht Institute of the Royal Netherlands Academy of Arts and Sciences and most recently served as President of the Royal Netherlands Academy of Science. His scientific research has focused on the biology of Wnt signaling in intestinal self-renewal and cancer.

Dr. Clevers discovered tissue stem cells in multiple organs through the Lgr5 stem cell marker. This led to establishment of organoid technology. He received his M.D., Ph.D., and M.Sc. in biology from the University of Utrecht with postdoctoral work completed at Dana-Farber Cancer Institute.

Antoni Ribas, M.D., Ph.D.

Dr. Ribas is a Professor of Medicine, Professor of Surgery, and Professor of Molecular and Medical Pharmacology at the University of California Los Angeles (UCLA). He also currently serves as Director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center (JCCC), Chair of the Melanoma Committee of the South West Oncology Group (SWOG) and a member of the Board of Directors of the American Association for Cancer Research (AACR).

Dr. Ribas is a physician-scientist who conducts laboratory and clinical research in malignant melanoma, focusing on gene engineered adoptive cell transfer (ACT) therapies, anti-CTLA4 antibodies, anti-PD-1 antibodies, BRAF and MEK inhibitors and nanoparticle-siRNA. He trained at the University of Barcelona with postdoctoral research and clinical fellowships completed at UCLA.

Ton Schumacher, Ph.D.

Dr. Schumacher is a Senior Member at The Netherlands Cancer Institute, Professor of Immunotechnology at Leiden University Medical Center, Venture Partner at Third Rock Ventures and a scientific advisor to several emerging biotechnology companies. Dr. Schumacher is also the Founder of Neon Therapeutics and AIMM Therapeutics. He previously served as Chief Scientific Officer of Kite Pharma EU, which was formed following Kite Pharma’s acquisition of T Cell Factory, a company

Dr. Schumacher founded. Dr. Schumacher received his Ph.D. from The Netherlands Cancer Institute, a M.Sc. in medical biology from the University of Amsterdam and completed a postdoctoral fellowship at the Massachusetts Institute of Technology.

Josep Tabernero, M.D., Ph.D.

Dr. Tabernero is the Director of the Vall d’Hebron Institute of Oncology (VHIO), Associate Professor in the Medicine Department at the Universitat Autònoma de Barcelona, and Director of Innovation, Care and Research at the Catalonian Oncology Network. Dr. Tabernero also holds several roles in the Medical Oncology Department at the Vall d’Hebron University Hospital, including Head of the Department, Clinical Director and Head of the Gastrointestinal Tumors Services and Phase 1 Unit.

Dr. Tabernero is a physician-scientist who conducts laboratory and clinical research in the field of gastrointestinal tumors with particular focus in early drug development. Dr. Tabernero received his M.D. and Ph.D. from the Universitat Autònoma de Barcelona.